Veracyte (VCYT) Tops Q4 EPS by 11c; Offers FY23 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. CRWV
2. NVDA
3. SPY
4. BAC
5. BLK
6. CAT
7. AA
8. RKLB
9. RXRX
10. NOW

Go back to Veracyte (VCYT) Tops Q4 EPS by 11c; Offers FY23 Revenue Guidance

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

February 22, 2023 4:05 PM EST

Grew Fourth Quarter Revenue to $80.3 Million

Grew 2022 Total Revenue to $296.5 Million

Conference Call and Webcast Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022.

We had an outstanding fourth quarter, driving record revenue and operating cash flows, achieving the best quarter ever for both our Decipher prostate and Afirma thyroid tests, said Marc Stapley, Veracytes chief executive officer. Moreover,... More